The main body of data indicates that the KDM6A/UTX demethylase protein acts as a tumour suppressor, and that tumours lacking or carrying mutations in KDM6A may, in some cancers, be targeted with either EZH2 or BET inhibitors. The gene discussed is EZH2; the disease is cancer.